UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of
1934
Date
of
report (Date of earliest event reported): August 7, 2008
AMERICAN
BIO MEDICA CORPORATION
(Exact
Name of Registrant as Specified in its Charter)
New
York
|
|
0-28666
|
|
14-1702188
|
(State
or Other Jurisdiction of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification Number)
|
122
Smith
Road, Kinderhook, NY
12106
(Address
of Principal Executive Offices)
(Zip
Code)
Registrant’s
telephone number, including area code: 518-758-8158
Not
applicable
(Former
name or former address, if changed since last report.)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13c-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM
1.01 Entry
into a Material Definitive Agreement
On
August
7, 2008, the Company entered into an amendment (the “Amendment”) to its Letter
Agreement (the “Letter Agreement”) with First Niagara Bank (“First Niagara”),
effective as of August 1, 2008. The Letter Agreement, as amended by the
Amendment, sets forth the understanding between the Company and Fist Niagara
related to the Company’s line of credit, term note and real estate mortgage held
by First Niagara (together, the “Credit Facilities”). The Forbearance Agreement
previously entered into between the Company and First Niagara with respect
to
the Credit Facilities and the Company’s non-compliance with certain financial
covenants set forth in the loan documentation for the Credit Facilities (the
“Loan Documents”) expired on July 31, 2008 (see the Company’s Current Report on
Form 8-K filed with the Securities and Exchange Commission (the “Commission”) on
May 28, 2008).
The
Amendment reduces the interest rate on the Company’s line of credit to prime
plus 1% (during the term of the Forbearance Agreement, the interest rate on
the
Company’s line of credit was prime plus 2%). The maximum amount available under
the line of credit remains unchanged at $750,000, and the maturity date of
the
line of credit has been extended to April 1, 2009.
The
Amendment also revises the financial covenants required to be maintained by
the
Company under the Letter Agreement. Under the Amendment, the Company’s monthly
net loss must not exceed $75,000 during any month and, while any loans or
commitments are outstanding and due First Niagara, the Company must maintain
a
minimum debt service coverage ratio of 1.10x, to be measured at December 31,
2008. The minimum debt service coverage ratio is defined as net income plus
interest expense plus depreciation plus expense related to the amortization
of
derivative securities divided by required principal payments over the preceding
twelve months plus interest expense.
In
the
event of default, the Company will be subject to an interest rate of prime
plus
6% under its line of credit, any default or breach by the Company of any of
the
terms, covenants and conditions set forth in the Letter Agreement or in any
Loan
Document shall constitute a default under the Letter Agreement, and all other
Loan Documents, and First Niagara may declare all sums outstanding under the
Credit Facilities due and payable without notice or demand.
Under
the
Letter Agreement, as amended by the Amendment, the Company is also required
to
sell at least $500,000 in subordinated debentures by September 1, 2008, on
terms
consistent with the term sheet agreed to between the Company and Cantone
Research, Inc. of Tinton Falls, New Jersey (“Cantone”) for the private placement
(the “Offering”) of an issue of Series A 10% Subordinated Convertible Debentures
(see below). As of the date of this report, the Company has entered into
Securities Purchase Agreements with investors for the sale of $608,000 of Series
A 10% Subordinated Convertible Debentures (the “Series A
Debentures”).
Under
Offering, not less than $250,000 nor more than $750,000 in principal amount
of
the Series A Debentures are to be placed. The Series A Debentures will accrue
interest at a rate of 10% per annum (payable by the Company semi-annually)
and
mature on August 1, 2012. The payment of principal and interest on the Series
A
Debentures is subordinate and junior in right of payment to all Senior
Obligations, as defined under the Series A Debentures. Holders of the Series
A
Debentures will have a right of conversion of the principal amount of the Series
A Debentures into shares (the “Conversion Shares”) of the common stock of the
Company (“Common Stock”), at a conversion rate of 666.67 shares per $500 in
principal amount of the Series A Debentures (representing a conversion price
of
approximately $0.75 per share). This conversion right can be exercised at any
time, commencing the earlier of (a) one hundred twenty (120) days after the
date
of the Series A Debentures, or (b) the effective date of a Registration
Statement to be filed by the Company with respect to the Conversion Shares.
The
Company has the right to redeem any Series A Debentures which have not been
surrendered for conversion at a price equal to the Series A Debentures’ face
value plus $0.05 per underlying common share, or $525 per $500 in principal
amount of the Series A Debentures. This redemption right can be exercised by
the
Company at any time within ninety (90) days after any date when the closing
price of the Common Stock has equaled or exceeded $2.00 per share for a period
of twenty (20) consecutive trading days.
As
placement agent, Cantone will be entitled to a Placement Agent fee equal to
7%
of the gross principal amount of Series A Debentures sold. In addition, Cantone
will receive warrants to purchase shares of Common Stock at the rate of 50
shares of Common Stock for each $500 in principal amount of Series A Debentures
placed. The warrants shall be exercisable within four (4) years of the issuance
date. The exercise price under the Warrants shall be: (i) a price equal to
the
publicly traded closing price of the shares of the Common Stock on the date
the
minimum in principal amount of Series A Debentures is placed by Cantone and
accepted by the Company (the “Closing Date”) with respect to the Series A
Debentures placed on the Closing Date and (ii), a price equal to the publicly
traded closing price of the shares of Common Stock on the date all Series A
Debentures able to be placed are placed by Cantone, and accepted by the Company
(the “Series A Completion Date”) with respect to the Series A Debentures placed
after the Closing Date and up through the Series A Completion Date.
Pursuant
to a Registration Rights Agreement, the Company has agreed to use reasonable
efforts to register the Conversion Shares and the shares of Common Stock
issuable upon exercise of the Placement Agent warrants.
The
securities to be issued in this transaction are being sold pursuant to the
exemption from registration afforded by Rule 506 under Regulation D ("Regulation
D") as promulgated by the Commission under the Securities Act of 1933, as
amended (the "1933 Act"), and/or Section 4(2) of the 1933 Act.
The
Company intends to update this Current Report on Form 8-K when additional Series
A Debentures are placed.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
|
AMERICAN
BIO MEDICA CORPORATION (Registrant)
|
|
|
|
Dated:
August 8, 2008 |
By: |
/s/ Melissa
A. Waterhouse |
|
Melissa
A. Waterhouse |
|
Vice
President & Chief Compliance Officer
Corporate
Secretary
|